Extending the User Fee Approach to Pharmaceuticals

JAMA. 2018 Oct 16;320(15):1525-1526. doi: 10.1001/jama.2018.14959.
No abstract available

MeSH terms

  • Drug Approval / economics*
  • Drug Industry / economics*
  • Fees and Charges*
  • Fellowships and Scholarships / economics*
  • Humans
  • Legislation, Drug
  • National Institutes of Health (U.S.)
  • Prescription Drugs / economics*
  • United States
  • United States Food and Drug Administration

Substances

  • Prescription Drugs